Breaking News

Roche’s SARS-CoV-2 Test Receives EUA

First commercial test for SARS-CoV-2 will enable expedited coronavirus testing with results in three and half hours

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

U.S. FDA has issued an Emergency Use Authorization (EUA) for Roche’s cobas SARS-CoV-2 Test. It is intended for the detection of SARS-CoV-2, the virus that causes COVID-19 disease, in swab samples from patients who meet COVID-19 clinical criteria for testing. Hospitals and reference labs can run the test on Roche’s automated cobas 6800 and cobas 8800 Systems, which are widely available in the U.S. and around the world. The cobas 6800/8800 Systems provide test results in three and half hours wi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters